You are viewing a preview of...

Development of Dry Powder Formulations of siRNA Nanoparticles for Inhalation

A platform for spray-drying siRNA nanoparticles to obtain nano-in-microparticles with ideal aerodynamic properties for inhalation


After the approval of Onpattro and Givlaari, siRNA therapy has become reality – however only for targets in the liver. While the lung is generally easily accessible by inhalation, formulation of siRNA, which generally has to be delivered by a nanocarrier, for inhalation is challenging.

To develop a spray-drying platform for pulmonary siRNA delivery against SARS-CoV-2, other respiratory viruses or genes pathologically (over)expressed in the lung in patients suffering from asthma, COPD, cystic fibrosis, lung fibrosis, or lung cancer, LMU Munich researchers have optimized spray drying process parameters, matrix excipients and tubing materials to decrease siRNA losses, decrease residual moisture of the powder formulation, optimize redispersion, maintain nanoparticle sizes, size distributions and zeta potentials and to ensure efficient gene

Log in or create a free account to continue reading